

## **Biohazard Risk Assessment**

To be completed prior to acceptance of a Cell Line into a European Collection of Authenticated Cell Cultures (ECACC) repository

For Culture Collections use only

Type of Deposit: Accession / Safe / Patent/ Sample for testing					
Accession Number(s):		Batch Number(s):			
ACDP Hazard Group:					
CBA-1 notification:	GMSC notification:				
Required / Not Required		Class 1 / 2 / 3 / Not Required			
required / Not required					
Comt	i d.				
Sent: Received:		Sent:	R	eceived:	
Containment Level:		Comment:			
Signature (Deposit approved):			Date		
For completion by [	Depositor:				
1. Depositor Inforr	mation				
1 0 0	0 110 1 4 4 11				
Institution	CellBank Australia				
Address	The Children's Medical Research Institute				
	214 Hawkesbury Rd				
	Westmead, NSW 2145 - Australia				
Title & name of	Director, Professor Roger Reddel				
Depositor	,				
I confirm that the details given here are full and true to the best of my knowledge.					
Signature	22	ue	Date	23 September 2021	

Effective Date: 03.06.2016

Cell Line Name	HeLa H2	B-2FP also known as HeLa-2FP, (CBA-1861)		
Tissue Type	Cervix, cervical carcinoma			
Species	Human			
Morphology	Epithelia	l-like		
3. Safety Inform	nation			
•	•	ed to a Hazard group: See Advisory Committee on Dangerous List of Biological Agents at <a href="https://www.hse.gov.uk/pubns/misc208.pdf">www.hse.gov.uk/pubns/misc208.pdf</a>		
Is the cell line known to contain or secrete a virus or virus-like particles?		Yes ☐ No ⊠ Further details		
ACDP Hazard Group		1 🗌 2 🖂 3 🗍 4 🗍		
Is the cell line listed under the UK Specified Animal Pathogen Order (SAPO)?		Yes ☐ No ⊠		
		ain/produce a biologically active substance that could cause cytokine, hormone, allergen, oncogene)?		
Yes ⊠ No □				
Further details: Ce	ells contain	E6 protein which degrades p53, functionally knocking it out		
Are you including any Risk Assessment performed at your site?		Yes \( \sum \) No \( \sum \)  If yes, please attach.		

2. Cell Line Identity

Effective Date: 03.06.2016

Please supply a Material Safety Data Sheet	Attached ☐ To follow ⊠
In light of your knowledge of this cell line and its origination, what is your assessment of its potential to cause harm to human health in the event of exposure?	Negligible ☐ Low ☐ Medium ☐ High ☐ If the answer is "medium" or "high" please provide further details:
Does this cell line have the ability to survive, establish, and disseminate in the environment?	Yes ☐ No ☒  If the answer is yes, please provide further details:
If you are sending ampoules to ECACC are they glass or plastic vials?  N.B. Plastic vials are the preferred option	Plastic Vials

**Important Note:** Organisms pathogenic to humans or animals are subject to import/ export license and transport regulations

## 4. Genetic Modification

Is the Cell Line Genetically	Yes ⊠ No □			
Modified?	If Yes, what Class?: 1 ⊠ 2 □ 3 □ 4 □			
Description of genetic modification of the cell line:  HeLa cells dually transduced with Retrovirus to stably express H2B tagged with GFP, from				
pWZL backbone, and H2B t				
What is the risk that the	Unlikely ⊠ Possible ☐ Demonstrated ☐			
genetic modification can confer pathogenic traits in the host cell/organism or related organisms?	If the answer is "possible" or "demonstrated" please provide further details:			
What is potential for	Unlikely ⊠ Possible □ Demonstrated □			
sequences in the cell line being transferred to another related organism?	If the answer is "possible" or "demonstrated" please provide further details:			

Effective Date: 03.06.2016

## Please note that Culture Collections may request further information in order to complete its risk assessment.

If you require any assistance completing this form, please contact

CultureCollections @phe.gov.uk

ECCW86.02-16 Authorised by: Karen Buttigieg Effective Date: 03.06.2016

Page 4 of 4